USA flag logo/image

An Official Website of the United States Government

A Nanofibrous Bioactive Prosthetic Sewing Cuff

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93938
Program Year/Program:
2009 / STTR
Agency Tracking Number:
HL095189
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOSURFACES
200 Homer Avenue, Unit 1P ASHLAND, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: A Nanofibrous Bioactive Prosthetic Sewing Cuff
Agency: HHS
Contract: 1R41HL095189-01A2
Award Amount: $110,528.00
 

Abstract:

DESCRIPTION (provided by applicant): Cardiac valve replacement using prosthetic valves is indicated when progression of degenerative disease or bacterial infection of the native valve results in valvular dysfunction, thereby impacting on cardiac output. An estimated 50,000 prosthetic valves are implanted annually in the United States, with this number increasing due to an aging population and, to a lesser extent, a more aggressive approach to mitral valve insufficiency. Bacterial infection (prosthetic valve endocarditis or PVE) and thrombosis/thromboembolisms are major complications associated with implantation of these valves. The goal of this Phase I STTR grant is to develop in vitro a novel nanofibrous polyester cuff that will simultaneously provide local ized infection-resistance and antithrombotic properties via release of selected agents over an extended period of time. Our hypothesis is that biologically-active agents can be incorporated into the bulk polymer solution followed by synthesis of the nanofi brous material via proprietary electrospinning technology. These agents can then be simultaneously released from the respective nPET materials in a slow, sustained fashion upon exposure to physiological conditions while maintaining biologic activity. Our p reliminary data supports this hypothesis. The specific objectives of this study are to: 1) optimize methodology for synthesizing nanofibrous polyester cuffs (nPET cuffs), 2) incorporate selected antimicrobial and antithrombin agents into the nPET cuff cons tructs (bioactive nPET cuffs), 3) characterize physical properties of novel bioactive nPET materials, 4) assess drug elution profiles from bioactive nPET cuffs over time under static and washing conditions using specific assays, 5) examine in vitro biologi cal properties of static and washed bioactive nPET cuffs using specific biologic assays and 6) evaluate control and bioactive nPET cuffs for in vivo infection-resistance using a rabbit dorsal subcutaneous implantation model. Current projections indicate th at a greater number of prosthetic mechanical valves will be implanted over the next ten years, with conservative estimates of 50,000 valves per year. The associated health care costs from PVE alone are projected to be 50,000 per patient with a projected a nnual market in excess of 25-75 million. This technology can also be applied to novel nanofibrous devices such vascular grafts, carotid patch material, catheter cuffs, wound dressings and suture material. In Phase II of this project, this novel technology will be evaluated in vivo using a high flow arterial model employed to evaluate previous cuff biomaterials for infection-resistance. PUBLIC HEALTH RELEVANCE: Cardiac valve replacement using prosthetic valves is indicated when progression of degenerative d isease or bacterial infection of the native valve results in valvular dysfunction, thereby impacting on cardiac output. Bacterial infection (prosthetic valve endocarditis or PVE) and thrombosis/thromboembolisms are major complications associated with impla ntation of these valves. The goal of this Phase I STTR grant is to develop in vitro a novel nanofibrous polyester cuff that will simultaneously provide localized infection-resistance and antithrombotic properties via release of selected agents over an exte nded period of time. Current projections indicate that a greater number of prosthetic mechanical valves will be implanted over the next ten years, with conservative estimates of 50,000 valves per year. The associated health care costs from PVE alone are pr ojected to be 50,000 per patient with a projected annual market in excess of 25-75 million.

Principal Investigator:

Matthew D. Phaneuf
5088818860
BIOSURFACES@VERIZON.NET

Business Contact:

Phaneuf
biosurfaces@verizon.net
Small Business Information at Submission:

BIOSURFACES
BIOSURFACES, INC. 171 MAIN STREET, SUITE 302 ASHLAND, MA 01721

EIN/Tax ID: 126250296
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
BETH ISRAEL DEACONESS MEDICAL CENTER
330 BROOKLINE AVENUE, BR 264
BOSTON, MA 2215
RI Type: Domestic nonprofit research organization